Prostaglandin-endoperoxide Synthase 2 (PTGS2) Gene Expression and Its Association with Genes Regulating the VEGF Signaling Pathway in Head and Neck Squamous Cell Carcinoma

Overview

Journal J Oral Biol Craniofac Res

Publisher Elsevier

Date 2023 Aug 10

PMID 37559688

Authors

Mehta Vedant Kamal

Rama Rao Damerla

Punit Singh Dikhit

Naveena An Kumar

Affiliations

Soon will be listed here.

Abstract

Introduction: The PTGS2 gene codes for the cyclooxygenase-2 (COX-2) enzyme that catalyzes the committed step in prostaglandin (PG) synthesis. Various and data suggest that prostaglandin E2 mediates as a signaling molecule for activating the VEGF signaling pathway (VSP), forming an association between COX-2 and VSP. Several chemotherapy regimens increasingly rely on preventing the synthesis of PGs. The targeted and metronomic chemotherapy agents, which suppress the COX-2 enzymes, have a major role in suppressing the oral cancer cascade. Hence, this study was designed to understand the pattern of PTGS2 expression and genes regulating VSP in head and neck cancers.

Methods: PTGS2 expression was analyzed in the TCGA database computationally with the help of the UALCAN web-server. The expression of VEGF signaling pathway genes was mined, and their expression pattern was determined. Co-expression analysis was done to elucidate the association between VEGF signaling genes and PTGS2. The ShineyGo web server was used for gene set enrichment.

Results: Significantly high PTGS2 expression was observed in tumor samples. Further genes regulating VEGF signaling were significantly overexpressed in tumor samples. Co-expression analysis results showed a significant positive correlation between PTGS2 and angiogenesis-regulating genes. The majority of the genes were enriched for angiogenesis pathways.

Conclusion: PTGS2 was significantly expressed in head and neck cancer, and its expression was associated with genes regulating angiogenesis.

Citing Articles

Integrating network pharmacology, molecular docking, and bioinformatics to explore the mechanism of sparganii rhizoma in the treatment of laryngeal cancer.

Zheng M, Zhang R, Yang X, Wang F, Guo X, Li L Mol Divers. 2025; .

PMID: 40009149 DOI: 10.1007/s11030-025-11142-5.

Interactions between NAD+ metabolism and immune cell infiltration in ulcerative colitis: subtype identification and development of novel diagnostic models.

Tian L, Gao H, Yao T, Chen Y, Gao L, Han J Front Immunol. 2025; 16:1479421.

PMID: 39975557 PMC: 11835821. DOI: 10.3389/fimmu.2025.1479421.

Lin F, Yang H, Huang Z, Li Y, Ding Q, Ye Y Front Pharmacol. 2024; 15:1464830.

PMID: 39605903 PMC: 11598444. DOI: 10.3389/fphar.2024.1464830.

Identification of key genes and pathways involved in T-DM1-resistance in OE-19 esophageal cancer cells through bioinformatics analysis.

Yazdani F, Mottaghi-Dastjerdi N, Shahbazi B, Ahmadi K, Ghorbani A, Soltany-Rezaee-Rad M Heliyon. 2024; 10(18):e37451.

PMID: 39309859 PMC: 11415672. DOI: 10.1016/j.heliyon.2024.e37451.

Ferroptosis and oral squamous cell carcinoma: connecting the dots to move forward.

Antonelli A, Battaglia A, Sacco A, Petriaggi L, Giorgio E, Barone S Front Oral Health. 2024; 5:1461022.

PMID: 39296524 PMC: 11408306. DOI: 10.3389/froh.2024.1461022.

References

Zhao L, Wu Y, Xu Z, Wang H, Zhao Z, Li Y . Involvement of COX-2/PGE2 signalling in hypoxia-induced angiogenic response in endothelial cells. J Cell Mol Med. 2011; 16(8):1840-55. PMC: 3822696. DOI: 10.1111/j.1582-4934.2011.01479.x. View

Tosetti F, Ferrari N, De Flora S, Albini A . Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002; 16(1):2-14. DOI: 10.1096/fj.01-0300rev. View

Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V . Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 2001; 3(1):53-61. PMC: 1505025. DOI: 10.1038/sj.neo.7900127. View

Giatromanolaki A, Sivridis E, Athanassou N, Zois E, Thorpe P, Brekken R . The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis. J Pathol. 2001; 194(1):101-8. DOI: 10.1002/path.842. View

Parikh P, Hingmire S, Deshmukh C . Selected current data on metronomic therapy (and its promise) from India. South Asian J Cancer. 2016; 5(2):37-47. PMC: 4873693. DOI: 10.4103/2278-330X.181623. View

van Meir H, Kenter G, Burggraaf J, Kroep J, Welters M, Melief C . The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. Anticancer Agents Med Chem. 2013; 14(2):190-203. DOI: 10.2174/18715206113136660372. View

Nor J, Christensen J, Mooney D, Polverini P . Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol. 1999; 154(2):375-84. PMC: 1850007. DOI: 10.1016/S0002-9440(10)65284-4. View

Pai R, Soreghan B, Szabo I, Pavelka M, Baatar D, Tarnawski A . Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002; 8(3):289-93. DOI: 10.1038/nm0302-289. View

Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y . A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology. 2013; 2(1):e22647. PMC: 3583931. DOI: 10.4161/onci.22647. View

10.

Chan L, Wang L, Chiang F, Lee K, Kuo P, Liang C . IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway. Oncotarget. 2016; 7(38):61820-61831. PMC: 5308693. DOI: 10.18632/oncotarget.11445. View

11.

Nathan C, Leskov I, Lin M, Abreo F, Shi R, HARTMAN G . COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer. 2001; 92(7):1888-95. DOI: 10.1002/1097-0142(20011001)92:7<1888::aid-cncr1706>3.0.co;2-z. View

12.

Pal A, Kundu R . Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020; 10:3116. PMC: 6985034. DOI: 10.3389/fmicb.2019.03116. View

13.

Rumzhum N, Ammit A . Cyclooxygenase 2: its regulation, role and impact in airway inflammation. Clin Exp Allergy. 2015; 46(3):397-410. DOI: 10.1111/cea.12697. View

14.

Xu L, Stevens J, Hilton M, Seaman S, Conrads T, Veenstra T . COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 2014; 6(242):242ra84. PMC: 6309995. DOI: 10.1126/scitranslmed.3008455. View

15.

Hla T, Bishop-Bailey D, Liu C, Schaefers H, Trifan O . Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol. 1999; 31(5):551-7. DOI: 10.1016/s1357-2725(98)00152-6. View

16.

Shen Y, Zhou C, Cao Y, Li Q, Deng H, Gu S . Expression profile and prognostic value of CXCR family members in head and neck squamous cell carcinoma. World J Surg Oncol. 2022; 20(1):259. PMC: 9382762. DOI: 10.1186/s12957-022-02713-z. View

17.

Kamal M, Rao M, Damerla R, Pai A, Sharan K, Palod A . A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma. Cancer Invest. 2022; 41(2):144-154. DOI: 10.1080/07357907.2022.2139840. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Ghosh N, Chaki R, Mandal V, Mandal S . COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010; 62(2):233-44. DOI: 10.1016/s1734-1140(10)70262-0. View

20.

Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J . Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1):92. PMC: 7944998. DOI: 10.1038/s41572-020-00224-3. View